Viridian Therapeutics Inc (VRDN)

Jul 25, 2025

What drives Viridian Therapeutics Inc. stock priceFree Stock Movement Tracking - PrintWeekIndia

Jul 25, 2025

Jul 25, 2025

Viridian Therapeutics Inc. Stock Analysis and ForecastTremendous return rates - Autocar Professional

Jul 25, 2025

Jul 25, 2025

What analysts say about Viridian Therapeutics Inc. stockLightning-fast growth - PrintWeekIndia

Jul 25, 2025

Jul 25, 2025

What makes Viridian Therapeutics Inc. stock price move sharplyProfit Focused Trade Alerts - Newser

Jul 25, 2025

Jul 24, 2025

How Viridian Therapeutics Inc. stock performs during market volatilityMarket Ready Callouts - Newser

Jul 24, 2025

Jul 24, 2025

Is Viridian Therapeutics Inc. a good long term investmentExplosive trading opportunities - Autocar Professional

Jul 24, 2025

Jul 23, 2025

Viridian Therapeutics’ Veligrotug Shows Durable Proptosis Response in Phase 3 TED Trial - MSN

Jul 23, 2025

Jul 22, 2025

Why Viridian Therapeutics Inc. stock attracts strong analyst attentionBreakout Level Watch - Newser

Jul 22, 2025

Jul 21, 2025

Teacher Retirement System of Texas Decreases Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Jul 21, 2025

Jul 19, 2025

(VRDN) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Jul 19, 2025

Jul 19, 2025

Principal Financial Group Inc. Acquires 30,392 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Jul 19, 2025

Jul 15, 2025

13 Best Low Priced Pharma Stocks to Buy Now - Insider Monkey

Jul 15, 2025

Jul 12, 2025

Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Cuts Target Price to $38 - 富途牛牛

Jul 12, 2025

Jul 12, 2025

Amalgamated Bank Has $34,000 Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Jul 12, 2025

Jul 11, 2025

Evercore ISI Lowers Viridian Therapeutics Price Target to $38 - AInvest

Jul 11, 2025

Jul 10, 2025

Viridian Therapeutics Sees Relative Strength Rating Improve To 79 - MSN

Jul 10, 2025

Jul 08, 2025

(VRDN) Investment Analysis - news.stocktradersdaily.com

Jul 08, 2025

Jul 07, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Rating of “Moderate Buy” from Analysts - Defense World

Jul 07, 2025

Jul 03, 2025

Viridian Therapeutics: Fueling R&D Breakthroughs Through Strategic Equity Incentives - AInvest

Jul 03, 2025

Jul 01, 2025

Is Viridian Therapeutics (NASDAQ:VRDN) A Risky Investment? - simplywall.st

Jul 01, 2025